High Costs and Unequal Access in Canada’s Drug System
An independent panel negotiates the price of each medication with manufacturers on behalf of the provinces and territories, after which each jurisdiction decides whether to publicly list the drug. This process can restart negotiations or abandon a drug altogether, creating wide regional disparities across the country.
Lowest Prices, Slowest Access
Because the panel secures the lowest possible price, Canada often pays less than other nations, yet it consistently ranks last among G7 members for timely access to new medicines. Only 18 % of the world’s available drugs reach public plans, compared with the OECD average of 28 %.
Human Impact of Bureaucratic Delays
When a treatment is not available, patients may forgo therapy entirely or turn to older, less effective options. Some Canadians travel abroad for care—a growing form of medical tourism—while others simply wait, losing precious time that could mean the difference between recovery and decline.
Canada’s Scientific Strengths versus Policy Constraints
Canadian researchers have a storied record of innovation, from discovering stem cells in 1961 to developing lipid‑nanoparticle technology in the 1980s that later enabled mRNA COVID‑19 vaccines, and introducing the first Ebola vaccine in 2014. These achievements demonstrate the nation’s expertise, infrastructure, and talent for creating breakthrough medicines.
Looking Ahead
With the United States adopting a Most Favored Nation policy that pressures other countries to match higher drug prices, Canada risks falling even farther behind in both innovation and access. Faster, more pragmatic decision‑making is needed to ensure that the country’s scientific prowess translates into timely, life‑saving treatments for all Canadians.
